

Stock	Buy / Short	Thesis	Current Price	Target Price
LZB	BUY	La-Z-Boy, Inc. strives to be the leading global provider of comfortable, stylish home furnishings. The furniture industry is growing, and the outlook is strong for the years to come. Combined with La-ZBoy's success in implementing the 4-4-5 Strategy and strong balance sheet, the company will continue to create value and increase the price of their stock.	\$ 25.89	\$ 33.47
NLNK	BUY	NewLink Genetics Corp (NLNK) is a BUY because of its growth potential and undervaluation. NLNK is awaiting FDA approval for a treatment called IMPRESS. This treatment would be used for pancreatic cancer which currently affects 50,000 annually. Over the past 30 years, there has been no decrease in the mortality rate of those suffering with pancreatic cancer. Getting approved would give the company significant growth because of the potential new customers that need the treatment. There is currently an undervaluation of the stock due to the expectation of future legislation restricting the markup that the company can charge on its treatments. The stock price had decreased in September and has yet to see a major back to where it was priced prior. Because of this, there is major upside and very little downside to the stock. The stock has a one-year target of \$44.41 making it a BUY with an upside potential of 22%.	\$ 36.50	\$ 44.41
TAYD	BUY	Taylor Devices, Inc. (TAYD) has had great growth in the past year, both on the top and bottom line. The main catalyst for that growth has been identified as the turnaround of the economy. For the immediate future, the use of seismic dampers, a premier product sold by Taylor Devices, Inc., is only set to increase thanks to the health of the current economy. The increased demand will be met by the corporation's decision to expand its production facility. Based on the limited competition and high barriers to entry, the firm will gain a strong foothold into the industry and will see continued value creation for some time to come; it is therefore a recommended buy.	\$ 16.44	\$ 19.77
ACOR	BUY	Acorda Therapeutics Inc, has been showing continuous revenue growth for more than ten years. The company has been cash flow positive for the past three years and has a strong and healthy balance sheet, even while financing three late stage and three early stage clinical trials. Moreover, Ampyra that currently account for about 89% of Acorda's revenue is doing very well. The sales volume increases significantly every quarters and the drug became a standard of care. Acorda owns five patents protecting Ampyra until 2027. The market forecasts are also positive for Acorda as the Multiple Sclerosis market is growing tremendously, especially in western countries, and as the number of people affected by neurological diseases is growing in general as it is today easier and easier to detect them. A buy of Acorda Therapeutics Inc. is therefore recommended with a one-year target price of \$51.88. Currently trading at \$28.19, it has an upside potential of 38.79%.	\$ 38.19	\$ 51.88

DNKN	BUY	<p>Dunkin' is among the leaders in the quick service restaurants (Q.S.R) industry, with over 19,000 restaurants operating in 60 countries.</p> <p>Thanks to its asset-light business model, the company has effectively been creating value, as evidenced by its positive ROIC/WACC ratio of 37.7, and will continue to do so by increasing its footprint both domestically and internationally. Dunkin' also benefits from strong customer loyalty, great brand awareness, and a lack of substitutes for customers who are used to their morning caffeine shot. The stock suffered from a harsh selloff in the weeks that led to the third quarter earnings call, which I believe creates an attractive entry point for a medium to long-term investment.</p>	\$ 42.24	\$ 59.00
------	-----	--	----------	----------